12.6.2017 12:48 | Business Wire
Kieran Murphy Appointed CEO of GE Healthcare, Succeeding John Flannery
GE Chairman and CEO Jeff Immelt announced today the appointment of Kieran Murphy as president and CEO of GE Healthcare, effective immediately. Murphy is currently president and CEO of GE Healthcare Life Sciences. Murphy succeeds John Flannery who has been appointed CEO and chairman elect of GE.
Murphy, 54, was appointed CEO of GE Healthcare Life Sciences in September 2011. Since then, he has overseen significant revenue growth and geographic expansion of the molecular medicine business, which now accounts for more than $4 billion in annual sales with 11,000 employees in more than 100 countries. GE Healthcare Life Sciences provides a broad range of industry-leading technologies and services for drug discovery, pre-clinical and clinical development and biopharmaceutical manufacturing, as well as molecular tools for diagnostics, therapy selection and treatment monitoring in patient care. The business is a leader in organic growth, margins and cash generation.
Immelt said: “In his career at GE, Kieran has demonstrated the right combination of talent and drive to step into this key leadership role at the company. Having led the strategic combination of GE’s Life Sciences and Medical Diagnostics units, Kieran is universally respected across GE and has distinguished himself as a strong customer advocate with great commercial instincts. Alongside the outstanding team at GE Healthcare, we anticipate that the business will experience continued global growth under Kieran’s leadership.”
“Kieran has proven to be a natural leader and has been instrumental in the tremendous growth we’ve seen across GE Healthcare Life Sciences,” said Flannery. “I am confident that under his leadership the GE Healthcare team will continue to innovate and execute, introducing new products and driving cost productivity.”
GE Healthcare, a $20 billion business, is the world’s leading manufacturer of medical imaging devices; life sciences tools to enable the next generation of biotherapeutics; medical diagnostic agents that enable personalized medicine; and healthcare IT and software tools to digitize and industrialize the healthcare industry. Healthcare is a key GE business now and in the future.
Murphy joined GE Healthcare in 2008 from Whatman plc, a global supplier of filters and membranes for laboratory research, life sciences and medical diagnostic applications. He has over 20 years’ experience in the global life sciences and biotechnology industry, beginning his career with Janssen Pharmaceutical, a division of Johnson and Johnson, followed by leadership roles with Mallinckrodt, veterinary medicines provider Vericore, Novartis, Adprotech, ML Laboratories and Innovata plc. Having earned his bachelor’s degree in 1984 from University College, Dublin, he subsequently graduated from the University of Manchester Institute of Science and Technology with a master’s degree in Marketing.
GE is the world's Digital Industrial Company, transforming industry with software-defined machines and solutions that are connected, responsive and predictive. GE is organized around a global exchange of knowledge, the "GE Store," through which each business shares and accesses the same technology, markets, structure and intellect. Each invention further fuels innovation and application across our industrial sectors. With people, services, technology and scale, GE delivers better outcomes for customers by speaking the language of industry. www.ge.com
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com .
William Spiers, Head of External Affairs
+44 7971 276757 / +44 1494 545278
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
NY-IFF/ZOOMESSENCE23.6.2017 14:48 | pressemeddelelse
IFF and ZoomEssence Announce Settlement of Lawsuit
BIOGEN23.6.2017 13:57 | pressemeddelelse
Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use
EUSA-PHARMA23.6.2017 13:38 | pressemeddelelse
EUSA Pharma Receive Positive Opinion from The CHMP For tivozanib For The First-Line Treatment of Advanced Renal Cell Carcinoma In The European Union
CA-GILEAD-SCIENCES,-INC.23.6.2017 13:37 | pressemeddelelse
European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes
SAMSUNG-BIOEPIS23.6.2017 13:32 | pressemeddelelse
Samsung Bioepis' Imraldi® (Adalimumab) Recommended for Approval by European Medicines Agency
MA-BLUEBIRD-BIO23.6.2017 13:02 | pressemeddelelse
bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum